GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
11 10월 2023 - 10:05PM
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a
biotechnology company advancing an innovative pipeline of Natural
Killer T (“NKT”) cell modulators for the treatment of inflammatory,
fibrotic and autoimmune diseases, today announced that Marc Hertz,
PhD, President and Chief Executive Officer will participate in the
Virtual Investor Ask the CEO Conference on Tuesday, October 24,
2023 at 11:00 AM ET.
The "Ask the CEO" Conference is intended to
provide the investment community with access to ask their questions
directly to management. Investors and interested parties will have
the opportunity to submit questions live during the event.
Questions can also be pre-submitted leading up to the event through
virtualinvestorco.com/asktheceo-gri. Participating companies will
answer as many questions as possible during the event.
A live video webcast of the event will be
available on the Events page of the Investors section of the
Company’s website (www.gribio.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical
company focused on fundamentally changing the way inflammatory,
fibrotic and autoimmune diseases are treated. GRI Bio’s therapies
are designed to target the activity of NKT cells, which are key
regulators earlier in the inflammatory cascade, to interrupt
disease progression and restore the immune system to homeostasis.
NKT cells are innate-like T cells that share properties of both NK
and T cells and are a functional link between the innate and
adaptive immune responses. Type I invariant NKT (“iNKT”) cells play
a critical role in propagating the injury, inflammatory response,
and fibrosis observed in inflammatory and fibrotic indications. GRI
Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity
and is being developed as a novel oral therapeutic for the
treatment of idiopathic pulmonary fibrosis, a serious disease with
significant unmet need. The Company is also developing a pipeline
of novel type 2 NKT agonists for the treatment of systemic lupus
erythematosus. Additionally, with a library of over 500 proprietary
compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:JTC Team, LLC Jenene Thomas
(833) 475-8247 GRI@jtcir.com
GRI Bio (NASDAQ:GRI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
GRI Bio (NASDAQ:GRI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024